Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + pegaspargase + etoposide + dexamethasone
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
The GPED regimen is a multi-agent chemotherapy protocol consisting of gemcitabine, pegaspargase, etoposide, and dexamethasone. It is primarily developed and investigated by Beijing Tongren Hospital for the treatment of relapsed/refractory or advanced extranodal NK/T-cell lymphoma (ENKTCL), including cases complicated by hemophagocytic lymphohistiocytosis. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by targeting ribonucleoside reductase and incorporating into DNA; pegaspargase is a pegylated form of L-asparaginase that depletes serum asparagine, an amino acid essential for the survival of lymphoma cells; etoposide is a topoisomerase II inhibitor that induces DNA strand breaks; and dexamethasone is a corticosteroid that provides lympholytic and anti-inflammatory effects. This combination therapy is designed to overcome the resistance often seen in advanced NK/T-cell lymphomas by utilizing multiple mechanisms of action.
- Other names
- GPED regimen
02
Targets
Pol (Replicative DNA polymerase)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)RNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on gemcitabine + pegaspargase + etoposide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + pegaspargase + etoposide + dexamethasone.